Introduction: The clinical impact of invasive hemodynamic support with Impella in patients
with cardiogenic shock (CS) remains to be defined. Methods: Only studies including patients …

Background The outcome of cardiogenic shock complicating myocardial infarction has not
appreciably changed in the last 30 years despite the development of various percutaneous …

Purpose Cardiogenic shock is associated with high mortality. In refractory shock, it is unclear
if mechanical circulatory support (MCS) devices improve survival. We conducted a network …

Background: Impella was approved for mechanical circulatory support (MCS) in 2008, but
large-scale, real-world data on its use are lacking. Our objective was to describe trends and …

Aims Despite its high incidence and mortality risk, there is no evidence‐based treatment for
non‐ischaemic cardiogenic shock (CS). The aim of this study was to evaluate the use of …

Impella was approved by the Food and Drug Administration in 2015 for use during high-risk
percutaneous coronary interventions (PCIs); however, its safety and efficacy compared with …

Percutaneous coronary intervention (PCI) is establishing as the last remaining
revascularization option in an increasing number of patients affected by complex coronary …

Background Percutaneous assist devices may be used as a bridge to recovery in patients
with acute myocardial infarction complicated by cardiogenic shock (CS-AMI). Aim To test the …

Background Protection against acute kidney injury (AKI) has been reported with the use of
Impella during high‐risk percutaneous coronary intervention (HR‐PCI). We sought to …

Background Acute kidney injury (AKI) is the most common complication after percutaneous
coronary intervention (PCI). Accurately estimating patients' risks not only creates a means of …